The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.